Addex Therapeutics to Report Q3 2025 Financial Results on December 4
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 01 2025
0mins
Source: Globenewswire
- Financial Report Announcement: Addex Therapeutics will report its Q3 2025 financial results on December 4 at 16:00 CET, which is expected to provide crucial updates on the company's product pipeline, aiding investors and analysts in understanding its developmental trajectory.
- Executive Update: CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev will provide a business update during the teleconference, likely discussing the progress of Addex's lead drug candidate, dipraglurant, particularly its potential applications in brain injury recovery.
- Investor Participation: Participants are required to register in advance to receive dial-in numbers and a personal PIN, ensuring a smooth conference call, which reflects the company's commitment to transparency and investor relations.
- Market Positioning: Focused on developing small molecule allosteric modulators for neurological disorders, Addex's upcoming financial report will be closely watched for updates on its drug development and partnerships, indicating its strategic positioning in the biopharmaceutical market.
Analyst Views on ADXN
About ADXN
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
